아토피 피부염 시장 : 현황 분석과 예측(2023-2030년)

The Atopic Dermatitis market is expected to register a CAGR of approx. 11.2% over the period of 2023-2030. Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by red, itchy, and inflamed patches of skin. It is a common condition that typically begins in infancy or childhood but can persist into adulthood. AD is believed to result from a combination of genetic, immune, and environmental factors, including defects in the skin barrier, immune system dysregulation, and exposure to allergens or irritants. Atopic dermatitis is a widespread chronic inflammatory skin condition, with its prevalence increasing globally, particularly in industrialized nations is boosting the atopic dermatitis(AD) market. For instance, According to the World Allergy Organization (WAO), AD prevalence ranges from 15% to 30% in children and 2% to 10% in adults globally. Moreover, with increasing healthcare expenditure worldwide, patients have greater access to healthcare services and treatments for chronic conditions like atopic dermatitis. For instance, According to a study published in JAMA Dermatology, the annual cost of atopic dermatitis in the United States exceeded $5.3 billion in 2018, with the majority of costs attributed to prescription medications and outpatient visits.

Based on the Drug Class, the market has been categorized into corticosteroids, pde4 inhibitors, calcineurin inhibitors, skin barrier emollients, others. Among them, the corticosteroids segment is expected to grow at a higher CAGR in the market due to several factors, including its well-established efficacy in managing inflammation and itching associated with AD, its widespread availability, and its relatively low cost compared to some newer treatment options. Corticosteroids, whether topical or systemic, have long been a mainstay in the treatment of AD, offering rapid relief of symptoms and helping to control flare-ups. As a result, they remain a popular choice among healthcare providers and patients for the management of mild to moderate AD and as adjunctive therapy in more severe cases.

Based on the end-user, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies. Among them, the hospital pharmacies category is to witness higher adoption of atopic dermatitis during the forecast period. The hospital pharmacy segment is experiencing growth in the atopic dermatitis (AD) market due to several factors, including the increasing prevalence of AD, the emergence of new treatment options, and the rising demand for specialized care in hospital settings. Hospitals play a crucial role in the management of AD, particularly in cases of severe disease requiring intensive therapy, multidisciplinary care, or access to advanced treatment modalities. Pharmaceutical companies continue to develop and introduce new treatment options for AD, including biologics, small molecule inhibitors, and novel topical formulations. Moreover, hospital pharmacies may offer specialized compounding services to tailor medications to the specific needs of AD patients.

For a better understanding of the market adoption of the Atopic Dermatitis industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America atopic dermatitis market is expected to continue to grow in the coming years, driven by the increasing prevalence of atopic eczema and growing awareness of atopic dermatitis among the general population, change in lifestyle. For instance, in 2020, according to national eczema.org, 31.6 million people (10.1%) in the U.S. have some form of eczema, and prevalence peaks during early childhood. It is estimated that 1 in 10 individuals will develop eczema during their lifetime, with prevalence peaking in early childhood.

Some of the major players operating in the market include Pfizer Inc., Abbvie Inc., Bristol Myers Squibb, Regeneron Pharmaceuticals, Inc., Evelo Biosciences, Inc., Sanofi, Novartis AG, GALDERMA LABORATORIES, L.P., Eli Lilly and Company (Dermira), Otsuka Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

1. MARKET INTRODUCTION

• 1.1.Market Definitions
• 1.2.Main Objective
• 1.3.Stakeholders
• 1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1.Research Process of the Atopic Dermatitis Market
• 2.2.Research Methodology of the Atopic Dermatitis Market
• 2.4.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE ATOPIC DERMATITIS MARKET

6. GLOBAL ATOPIC DERMATITIS MARKET REVENUE, 2020-2030F

7. MARKET INSIGHTS BY DRUG CLASS

• 7.1.Corticosteroids
• 7.2.PDE4 Inhibitors
• 7.3.Calcineurin Inhibitors
• 7.4.Skin Barrier Emollients
• 7.5.Others

8. MARKET INSIGHTS BY END USER

• 8.1.Hospital Pharmacies
• 8.2.Retail Pharmacies
• 8.3.Online Pharmacies

9. MARKET INSIGHTS BY REGION

• 9.1NORTH AMERICA ATOPIC DERMATITIS MARKET
  • 9.1.1.U.S.
  • 9.1.2.Canada
  • 9.1.3.Rest of North America
• 9.2EUROPE ATOPIC DERMATITIS MARKET
  • 9.2.1.Germany
  • 9.2.2.U.K.
  • 9.2.3.France
  • 9.2.4.Italy
  • 9.2.5.Spain
  • 9.2.6.Rest of Europe
• 9.3ASIA PACIFIC ATOPIC DERMATITIS MARKET
  • 9.3.1.China
  • 9.3.2.Japan
  • 9.3.3.India
  • 9.3.4.Rest of Asia-Pacific
• 9.4REST OF THE WORLD ATOPIC DERMATITIS MARKET

10. ATOPIC DERMATITIS MARKET DYNAMICS

• 10.1.Market Drivers
• 10.2.Market Challenges
• 10.3.Impact Analysis

11. ATOPIC DERMATITIS MARKET OPPORTUNITIES

12. ATOPIC DERMATITIS MARKET TRENDS & INSIGHTS

13. DEMAND AND SUPPLY SIDE ANALYSIS

• 13.1.Demand Side Analysis
• 13.2.Supply Side Analysis

14. VALUE CHAIN ANALYSIS

15. PRICING ANALYSIS

16. COMPETITIVE SCENARIO

• 16.1.Competitive Landscape
  • 16.1.1Porter's Five forces analysis

17. COMPANY PROFILED

• 17.1.Pfizer Inc.
• 17.2.Abbvie Inc.
• 17.3.Bristol Myers Squibb
• 17.4.Regeneron Pharmaceuticals, Inc.
• 17.5.Evelo Biosciences, Inc.
• 17.6.Sanofi
• 17.7.Novartis AG
• 17.8.GALDERMA LABORATORIES, L.P.
• 17.9.Eli Lilly and Company
• 17.10.Otsuka Pharmaceutical Co., Ltd

18. DISCLAIMER